Healthcare

Report by Bios Research

Bios' top 5 short ideas for 2024 had an 80% hit rate with Moderna the standout performer (down ~60%). For 2025, they select: 1) ~$13bn facilities and services company to be materially impacted by changes in reimbursement and by the growth in GLP1. 2) ~$6bn medtech company to be significantly impacted by new competitive launches. 3) ~$20bn commercial pharma/biotech company to suffer a notable decline in sales y/y and poor regulatory environment. 4) ~$3bn healthcare services and development company that is grossly overhyped and is burning excessive amounts of cash. 5) ~$1.5bn commercial launch failure in the biotech space that is grossly overhyped and could see greater than 80% decline in 2025.